On February 10, 2026 Protai, www.protai.bio, an AI drug discovery startup, reported its participation in a series of major scientific conferences this spring, where it will present significant advances in its AIMS proteomics-aware-AI drug discovery platform and breakthrough preclinical results of its best-in-class KAT6A degrader program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Protai’s upcoming spring 2026 conference presentations:
HDX-MS conference Strasbourg, 9-13 March 2026, Dr. Anjana Shenoy, Head of Proteomics
ACS2026, Atlanta, March 2026, Kirill Pevzner, CTO
TPD summit Europe, London, March 2026, Eran Seger (CEO) & Kirill Pevzner (CTO)
Drug discovery chemistry, San Diego, April 2026, Kirill Pevzner (CTO)
AACR 2026, San Diego, April 2026, Eran Seger (CEO) & Kirill Pevzner (CTO)
Protai’s presentations will highlight the following key achievements:
AIMS Platform validated: Integration of AI-driven structural modeling with mass-spectrometry-based structural proteomics, which supported the lead optimization of the KAT6A Targeted Protein Degradation program.
PRT-001 best-in-class results: New in vivo results from the company’s KAT6A degrader program.
"By combining proteomics-driven experimental evidence with next-generation AI modeling, we are revealing opportunities that were previously invisible to classical drug discovery methods." Said Eran Seger, Protai’s CEO. "These upcoming presentations will showcase the power of combining experimental data and AI, and its outcome in rapidly generating highly effective drugs for huge clinical unmet needs. "
(Press release, Protai Bio, FEB 10, 2026, View Source [SID1234662580])